JWATM-213

N/A

Report date: 2023/01/04 15:14:37

Base Information

Drug NameJWATM-213
Drug Alias NameJWATM-213JWATM213
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy
Mechanisms of ActionAlpha-fetoprotein modulators
TargetsAlpha-fetoprotein
Therapy Area/IndicationsCarcinoma, Hepatocellular
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesSuzhou Yaomingjunuo Biotechnology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesEureka Therapeutics IncLyell Immunopharma IncSuzhou Yaomingjunuo Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsCarcinoma, Hepatocellular
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A